Baichan, PNaicker, PrevinDevar, JWSSmith, MCandy, GPNweke, E2020-03-092020-03-092020-02Baichan, P. et al. 2020. Targeting gallbladder cancer: a pathway based perspective. Molecular Biology Reports, vol. 47: 2361-23690301-48511573-4978https://link.springer.com/article/10.1007/s11033-020-05269-xhttps://doi.org/10.1007/s11033-020-05269-xhttps://rdcu.be/b2GGGhttp://hdl.handle.net/10204/11321Copyright: Springer 2020. Due to copyright restrictions, the attached PDF file only contains the abstract of the full text item. For access to the full text item, please consult the publisher's website: https://link.springer.com/article/10.1007/s11033-020-05269-x . A free fulltext non-print version of the article can be viewed at https://rdcu.be/b2GGGGallbladder cancer (GBC) has a poor prognosis with a 5-year survival rate suggesting the need for more effective treatment strategies. Studying the cross-talk of several pathways involved in crucial cellular and biological processes such as cell growth, proliferation, migration and apoptosis would prove beneficial in identifying key players of GBC progression and targeting them. This review highlights several pathways known to be dysregulated in GBC onset and progression and describes known and potential targets. Within these pathways, there are proteins involved in the signalling cascade, which may be targeted as potential biomarkers and drug targets. Furthermore, the cross-talk of these pathways is investigated in the context of GBC and the implications thereof. A better understanding of the pathways involved in GBC pathogenesis will aid clinicians in the prognosis, diagnosis and treatment of patients. There are significant clinical implications of GBC pathway-based studies as they permit the understanding of onset and progression of the disease.enCC0 1.0 UniversalBiomarkersGallbladder cancerPathwaysArticleBaichan, P., Naicker, P., Devar, J., Smith, M., Candy, G., & Nweke, E. (2020). Targeting gallbladder cancer: a pathway based perspective. http://hdl.handle.net/10204/11321Baichan, P, Previn Naicker, JWS Devar, M Smith, GP Candy, and E Nweke "Targeting gallbladder cancer: a pathway based perspective." (2020) http://hdl.handle.net/10204/11321Baichan P, Naicker P, Devar J, Smith M, Candy G, Nweke E. Targeting gallbladder cancer: a pathway based perspective. 2020; http://hdl.handle.net/10204/11321.TY - Article AU - Baichan, P AU - Naicker, Previn AU - Devar, JWS AU - Smith, M AU - Candy, GP AU - Nweke, E AB - Gallbladder cancer (GBC) has a poor prognosis with a 5-year survival rate suggesting the need for more effective treatment strategies. Studying the cross-talk of several pathways involved in crucial cellular and biological processes such as cell growth, proliferation, migration and apoptosis would prove beneficial in identifying key players of GBC progression and targeting them. This review highlights several pathways known to be dysregulated in GBC onset and progression and describes known and potential targets. Within these pathways, there are proteins involved in the signalling cascade, which may be targeted as potential biomarkers and drug targets. Furthermore, the cross-talk of these pathways is investigated in the context of GBC and the implications thereof. A better understanding of the pathways involved in GBC pathogenesis will aid clinicians in the prognosis, diagnosis and treatment of patients. There are significant clinical implications of GBC pathway-based studies as they permit the understanding of onset and progression of the disease. DA - 2020-02 DB - ResearchSpace DP - CSIR KW - Biomarkers KW - Gallbladder cancer KW - Pathways LK - https://researchspace.csir.co.za PY - 2020 SM - 0301-4851 SM - 1573-4978 T1 - Targeting gallbladder cancer: a pathway based perspective TI - Targeting gallbladder cancer: a pathway based perspective UR - http://hdl.handle.net/10204/11321 ER -